China Linezolid Investigation Report 2015

Sep 03, 2015, 09:10 ET from Research and Markets

DUBLIN, Sep. 03, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jbhw6c/investigation) has announced the addition of the "Investigation Report on China Linezolid Market, 2010-2019" report to their offering.

Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).

Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram- positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin- resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013- 2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid's crystal form shall expire in 2021, its price stays high.

Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.

Key Topics Covered:

1 Related Concepts of Linezolid

2 Market Profile of Linezolid in China

3 Survey on Sales Status of Linezolid in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Linezolid in China, 2010-2014

5 Survey on Dosage Forms of Linezolid in China, 2010-2014

6 Reference Price of Linezolid in Chinese Hospitals in 2014

7 Major Manufacturers of Linezolid in Chinese Market, 2010-2014

8 Market Outlook of Linezolid in China, 2015-2019

Companies Mentioned

- Fresenius Kabi
- Pfizer Inc. (the US)
- Pharmacia & Upjohn

For more information visit http://www.researchandmarkets.com/research/jbhw6c/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com